Guidelines for ATC classification and DDD assignment - WHOCC

The DDDs are mainly based on prophylaxis of allograft transplant
rejection.
The DDD for muromonab-CD3 is based on combination therapy in
acute allograft rejection.
The DDD for efalizumab is based on the treatment of plaque psoriasis.
The DDDs for etanercept, infliximab, leflunomide, anakinra and
adalimumab are based on the treatment of rheumatoid arthritis.
The DDD for certolizumab pegol is based on the treatment of Crohn’s
Disease.
The DDD for thalidomide is based on the treatment of erythema
nodosum leprosum.
The DDD for lenalidomide is based on the treatment of
myelodysplastic syndromes.
L04AA Selective immunosuppressants
Antilymphocyte immunoglobulin from horse serum is classified in
L04AA03.
Antithymocyte immunoglobulin from rabbit serum is classified in
L04AA04.
L04AB Tumor necrosis factor alpha (TNF-�) inhibitors
L04AC Interleukin inhibitors
L04AD Calcineurin inhibitors
L04AX Other immunosuppressants
Methotrexate in oral formulations is classified here, other routes of
administration, see L01BA.
191